AU592997B2 - Tick vaccine - Google Patents

Tick vaccine Download PDF

Info

Publication number
AU592997B2
AU592997B2 AU59707/86A AU5970786A AU592997B2 AU 592997 B2 AU592997 B2 AU 592997B2 AU 59707/86 A AU59707/86 A AU 59707/86A AU 5970786 A AU5970786 A AU 5970786A AU 592997 B2 AU592997 B2 AU 592997B2
Authority
AU
Australia
Prior art keywords
tick
antigenic material
antigenic
vaccine
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU59707/86A
Other versions
AU5970786A (en
Inventor
Johanna P. Opdebeeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pitman Moore Australia Ltd
Original Assignee
Coopers Animal Health Australia Ltd
Coopers Animal Health NZ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coopers Animal Health Australia Ltd, Coopers Animal Health NZ Ltd filed Critical Coopers Animal Health Australia Ltd
Priority to AU59707/86A priority Critical patent/AU592997B2/en
Publication of AU5970786A publication Critical patent/AU5970786A/en
Application granted granted Critical
Publication of AU592997B2 publication Critical patent/AU592997B2/en
Assigned to PITMAN-MOORE AUSTRALIA LIMITED reassignment PITMAN-MOORE AUSTRALIA LIMITED Request to Amend Deed and Register Assignors: COOPERS ANIMAL HEALTH AUSTRALIA LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

r 592997 COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952 COMPLETE SPECIFICATION FOR OFFICE USE Form Short Title: Int. Cl: Application Number Lodged 0- /C4 PH 01310 3 July 1985 Complete Specification-Lodged: Accepted: Lapsed: Published: 0 4 #4 4 o44 0 4 o 44 t el o~l Priority: 7 Related Art: TO BE COMPLETED BY APPLICANT Name of Applicant: Address of Applicant: Actual Inventor: Address for Service: COOPERS ANIMAL HEALTH AUSTRALIA
LIMITED
71 Epping Road, North Ryde, New South Wales 2113, Australia JOHANNA PATRICIA OBDEBEECK GRIFFITH HASSEL FRAZER 71 YORK STREET SYDNEY NSW 2000
AUSTRALIA
Complete Specification for the invention entitled: TICK VACCINE The following statement is a full description of this invention, including the best method of performing it known to me:- 4446 A/MS
I
'A'
4.
a r i; I i This invention relates to antigenic compositions and in particular to vaccines for the control of tick infestations on animals.
In many countries the control of tick infestations on animals, particularly cattle, is a problem of considerable economic significance. Even with miild infestation there is a loss in meat and milk production and hide damage, and with heavier infestations the ticks must be removed to avoid death of the cattle. Tick, are also disease carriers of, for example, Babesia parasites which lead to outbreaks of "tick fever".
The traditional method of control has involved the use of sprays or dipping vats with various chemicals, such as DDT, chlorinated hydrocarbons, car'bamates, organophosphates, pyrethroids, and amidines. Most of these chemicals have had a limited period of commercial use because various strains of ticks emerged which were resistant to them. In some cases it was possible to S extend the usefulness of a particular chemical by increasing the concentration of the chemical in the spraying or dipping fluid, but this increased the cost and frequently toxic symptoms were observed in the cattle. In general the dipping or spraying treatment needs to be repeated every three to four weeks and there are .999 additional high labour costs involved in mustering the animals and moving them to and from the dipping or spraying sites.
There are further difficulties associated with the use of these chemicals. Where the chemicals are used in a concrete dipping vat set in the ground there is considerable contamination of the dip contents by urine and faeces from the cattle leading to decomposition and hence additional loss of the chemicals, and necessitating regular chemical analyses to monitor the level of the active ingredient. The dips need to be cleaned periodically and this leads to exposure of workers to potentially hazardous chemicals. Furthermore, the 4174S/MS 1A-
\I
iix*: I I
I.
1 disposal of dipping fluids has to be done with care to avoid environmental damage.
A further difficulty in the use of chemicals lies in the increasingly difficult task of finding new effective chemicals to combat each new resistant tick strain as it emerges. Part of this difficulty is compounded because it is desirable that the new chemical leaves minimal residues in the meat and milk of the host animal, and that such residues that are left are not harmful to consumers.
Thus for many decades there has been an urgent need for alternative safe and cost-effective means of controlling tick infestations to cattle, Management approaches such as pasture spelling have limited effectiveness and in most cases the required areas of land i*.15 are simply not available. Attempts to breed tick-resistant cattle have continued for many years with little impact on the problem. Eradication campaigns have e *0 been tried and have given limited success in some areas, S* albeit at high cost, but are impracticable in view of the very large areas which may be involved.
We have now discovered an effective method of tick control which does not require the use of hazardous chemicals, and since a single treatment is effective for extended periods the need For regular mustering is eliminated. This method depends on the capacity of the animal's immune systems to prevent tick survival or development on the animal.
Use o 4 resistant cattle for the control of cattle tick has been suggested as a supplement to tick control by S* 30 chemicals. The stimulus of tick infestation is normally required before resistance is manifested; this resistance is "acquired" and is presumed to be immunologically mediated. However the degree of resistance which an individual bovine can develop is a heritable characteristic which varies widely according to breed.
Some breeds, for example Zebu and part Zebu crossbreeds develop high levels of resistance while others, such as S4174S/MS 2 -i 'A'riS53 ibmost British breeds, remain largely susceptible. Despite extensive selective breeding programs, howiever, this natural resistance has not provided a satisfactory alternative or supplement to the chemical control of ticks, The possibility of developing a Lick vaccine has been suggested previously. Whole tick homogenates, salivary antigens, gut-associated antigens and certain purified proteins or enzymes have been used by various workers (See Allen and Humphries, Nature (1.979) 280, 491-493) and some have produced levels of immunity which are significant but still inadequate by comparison with chemical methods of control, Uarious explanations for this limited success have been proosed; for example, that vaccines cannot be expected to produce a greater resistance than the naturally acquired resistance that is characteristic of the breed concerned, that whole tick homogenates include immuno-suppressive components, and that purified antigens are inadequate and require synergy with other antigens.
Australian patent specification 45936/85 discloses an attempt to prepare tick antigens by purification of crude whole tick extracts, However, the reported level of S isolation of useful antigens is low.
"The present invention for vaccinating cattle against cattle tick confers a high long-lasting level of resistance on naive cattle of breeds which characteristically develop only a small degree of natural 1* resistance. The efficacy of the vaccine is such as to offer a very satisfactory alternative to chemical control, as well as the advantage of very infrequent treatments.
Accordingly we provide an antigenic composition which comprises antigenic material derived from the synganglion of a tick, It is found that antigenic material derived from the synganglion the central nervous system of the tick) extends and improves the protection given by other antigens e.g. those prepared from the tick gut alone.
While we do not wish to be limited by discussion 4174S/MS 3 of the possible underlying basis for our invention, it is possible that there are materials in I-he whole body of the tick that interfere with the generation of an effective immune response otherwise stimulated by the antigens of the synganglion. Thus, in a further embodiment of our invention we provide a mixture wherein the antigens are derived from both the synganglion and the gut of the tick.
In another aspect of our invention, we provide a vaccine for the protection of warm-blooded animals against ticks prepared from antigens which are obtained by dissection of synganglia or other nerve tissues from adult ticks. The dissected tissues may be homogenized, sonicated and centrifuged. The resulting mixture of antigens comprises both water-soluble and particulate '15 materials. We have found the particulate fraction to be more antigenic.
In a preferred aspect of our invention, the antigenic materials are obtained from larval ticks. The advantage of this method lies in the higher proportion of synganglion in the body-oeight of the larval tick compared to that of the nymph or adult stages of the ticks. The larval. ticks may be extracted by grinding or homogenizing or otherwise disrupting the ticks, followed by extraction ith suitable aquecus media, fractionation by suitable methods of affinity chromatography, gel permeation chromatography, ion-exchange chromatography, hydrophobic gel chromatography, electrophoresis, electrofocussing, selective precipitation, and concentration to provide the S final antigenic materials enriched in the antigenic components.
In a further embodiment of our invention, antigenic materials are obtained by disruption of developing tick eggs at the stage when the materials are first synthesized in the grouiing embryo.
The antigenic materials may also be obtained by cloning and expression of tick genetic material 4174S/MS 4 O lt l- ammUm mum in suitable host organisms, including bacteria, yeasts and other microorganisms and in cultured mammalian cells.
In another embodiment of our invention, antigenic materials characteristic of the synganglion are obtained by in vitro culture of tick cells or tick cells hybridized with other animal cells.
In a further aspect of our invention, antigenic materials, including but not limited to those characteristic of the synganglion, are obtained by affinity chromatography or immune precipitation or otherwise using serum antibodies of warm-blooded animals successfully immunized with tick antigenic material, or using monoclonal antibodies which bind specifically to tick antigenic material.
444 1 5 In a further embodiment of our invention antigenic materials are obtained by binding to Immobilized ligands which are related to known functional molecules of the nervous system, for example neutrotransmitter molecules, S or growth factors characteristic of nervous systems, or their derivatives respectively.
In a still further embodiment, immune suppressive I components from other tick tissues are inactivated and S" then added to the antigen mixture, so as to evoke an anti-suppressive response The antigenic materials are combined with one or more suitable adjuvants known to those skilled in the art, for example saponins (or derivative or related material), muramyl. dipeptide, trehalose dimycollate, Freund's Scomplete adjuvant, Freund's incomplete adjuvant, other water-in-oil emulsions, double emulsions, dextran, diethylaminoethyl-dextran, potassium alum, aluminium phosphate, aluminium hydroxide, bentonite, zymosan, polyelectrolytes, retinol, calcium phosphate, protamine, sarcosine, glycerol, sorbitol., propylene glycol, carboxyvinyl polymers available under the registered trade mark "Carbopol", fixed oils and synthetic esters of higher 4174S/MS '4' fatty acids. Sapon'Ins have been found 1-0 be particul hrly effective adjuvants.
The antigeniic material. may be treated with a suitab'le preservei',Ave Aincluding for example phenol., "Phenonip", formaldehyde, propylene glycol, glycerol, esters of p-hydroxybenzoic acid, benzoic acid and its sodiuim salt, hexachlorophene, quaternary germicides, sodium azide and thiomersal. used as such or in the Form In which it is available under, the registered trade mark "Merthiolate".
The antigenic material may be sterilized prior to or after formulation as appropriate, by filtration, irradiation or chemical treatment.
The antigenic material may also be coupled chemically or physically to a sui.ltable carrier, such as latex particles, or, immunogenic macro-molecules, or agarose beads or suchlike, or I~t may be formulated as antigen complexed with bovine or other antibodies.
The antigenic material, may a-lso be treated with a 4 suitable inhibitor, modifier, crosslinker or denaturant, or by hea- or irradiation, in such a way as to conserve or enhance it-s immunogenic efficacy.
The antigenic material may ailso be used iin
L
combination with other therapeutic agents such as 4 anthelmintIcs, for example levamisole or its therapeutically acceptable salts, flukicides and other vacci.nes, for exaimple clostridial vaccines, :1 The antigenic material may also be used in combination with irnmunostimnulatory agents such cis levamisole, bestatin, tuftsin, lectine, bacteria, l.1popoly sac charides, ,polynucleotides, tilorone, lentinan, isoprinosine, lysolecithin, and the. like, or with immunoregulatory hormones such as interleukins leukotrienes and the like or' with compositions of the natuvre of transfer factor, The antiganic material may be freeze-dried or otherwise dried or concentrated, and reconstituted just prior to use by addition of a suitable liquid medium, for 1 1745/MS -6example a sterile saline solution, optionally with the addition of one or more adjuvants or other additive materials alluded to above.
The antigenic material Formulated by any of the means described is henceforth termed the vaccine.
The amount of the vaccine administered to the animal will depend on the bodyweight of the animal and the relative activity of the particular preparation of antigenic material. Preferably the u.rcine is formulated in such a manner that sufficient antigen to protect the animal is contained in a volume of from 1. to 10 ml of vaccine, and more preferably in 1 to 5 ml of uaccine. The amount of antigenic material required is very small an'd typically samples of antigenic material containing less 15 than 2 mg of protein (preferably 10-1000 micrograms for cattle, particularly 50-500 micrograms) are sufficient for effective immunLnization of the animals against tick infestation. For other animal.s e.g. dogs or poultry correspondingly smaller doses wlould be used.
The preferred mode of administration of the vaccine S. is parenteral. The term "parenteral" is used herein to mean intravenous, intramuscular, intradermal, and subcutaneous injection. The administration is most conveniently carried out by intramuscular injection. The conventional injection guns used for other therapeutic applications with cattle may conveniently be used.
The vaccine may be used for the control or eradication of, or protection from infestation by, the various Ixodid ticks, including species such as Boophilus spp., Rhipicc.phalus spp., Ixodes spp., Hyalomma spp., Amblyomma spp., Dermacentor spp., and Haemaphysalis spp.
The vaccine may also be administered in the form of a depot or slow-release device or controlled-release device implanted in or attached to any part of the animal.
The novel method for the control of kicks provided by the inventiorn has a number of advantages, As mentioned hereinbefore the method of the invention avoids the use of hazardous chemicals with the attendant difficulties of 41741S/MS 7 'f t r $i 1 111..
maintaining and cleaning dipping vats and spraying equipment, but there are many additional advantages.
These additional advantages include the ease of combninng treatment for control of ticks with other 5 therapeutic treatments, the simple labour-saving method required for administration, elimination of possibly toxic insecticides being added to the environment, prevention of the development of resistant strains of ticks, and long periods of protection. This period of protection is advantageous both in reducing the need for regular treatments and because animals are protected at the start of each new tick season wlhen the number of ticks in the pastures is low and likely to go unnoticed. In most situations an annual vaccination wlill be sufficient to 15 confer year-round protection of animals from tick attack.
The effect of the vaccine is not only to reduce the yield of ticks from infested cattle, but also to reduce the viability and ferti.lity of the surviving ticks so that few eggs, generally of low viability, are produced. This 20 phenomenon accentuates the effect of widespread vaccination in reducing contamination of pasture with ticks.
4.
I
*1t 4( 41 S tb
S
4 f t *9 411~ S. I
S
4 t 4t t In the case of the cattle tick, Boophilus microplus, has a single host in its complete life cycle, the extended period of protection will also have the effect of steadily reducing the tick levels in the pastures and this effect will accumulate from year to year, A similar effect will occur with multihost ticks, The invention is now illustrated by, but by no means limited to, the following Examples, EXAMPLE I Two Hereford calves, without prior exposure to ticks, were vaccinated with antigen preparations prepared by homogenizing guts a-id synganglia obtained by dissection of adult cattle tick (Boophilus microplus). Patriculate and water-soluble fractions were obtained by centrifugation.
The particulate fraction was administered as a suspension 4174S/MS 8
I
f r
I
1 with saponin (Quil the soluble fraction was emulsified with Freund's incomplete adjuvant, and the two were injected subcutaneously at different sites. The vaccines were administered three times, on days 0, 14 and 4-5 of the trial. The doses included 500 micrograms of soluble antigen protein on each occasion, and 350, 100 and 100 micrograms of particulate antigen protein on the three days respectively.
A similar pair of calues was tested at the same time wiAth the adjuvants only, and a third pair was untreated.
The calves were challenged on days 62, 69, 76, 83 and with 20,000 larual ticks on each occasion All the adult ticks which dropped from the calues were counted and incubated until oviposition was .15 complete. Ticks which were abnormal in size or appearance iwere also noted and incubated separately.
The table gives the cumulative totals for normal and abnormal ticks and for the eggs produced. The vaccinated calues yielded the followig reductions relative to the control calues: Total ticks reduced by SNormal ticks reduced by 96% 9* Total eggs reduced by 98% Mean weight of normal ticks reduced by Mean weight of eggs produced by normal ticks reduced by 66% TABLE 1 9* 30 41i 2 k r E Total. Tick Normal Tick Eggs(g) Adj uuant controls 30,200 25,120 2,239 Vaccinated gut 4,900 910 synganglion 74S/MS 9 b I r 4 EXAMPLE II Preparation of tick vaccine, using affinity chromatography to extract protective antigens from larval tick komopenatet Summary A) Production of Antiserum Guts and synganglia are dissected from adult ticks Vaccines are prepared from these organs and administered to cattle.
The cattle are infested with ticks and shown to be highly immune.
B) Preparation of Affinity Column Serum is prepared from the immune cattle from antibodies are extracted from the serum, and bonded to chromatographic support.
C) Chromatographic Extraction of Antigens 4. Larval ticks are homogenised and separated into S* soluble and particulate fractions S* Both fractions are applied to the immobilised serum antibodies from (B) Antigens i.hich bind to the immobilized antibodies are eluted formulated as a vaccine 1 D) Vaccination of Cattle cattle vaccinated with the artigens obtained from (C) are su'-tantially immune to tick infestation, whereas whole larval tick homogenates are ineffective in 4, vaccination.
It 4 4 A) PRODUCTION OF ANTISERUM Collection of tick organs. Female ticks (Boophilus microplus) were collected manually from 2 Hereford cattle following the moult to young adult (day 14-17 of the life cycle) The ticks were embedded in wax and the following organs were dissected out: 1. Synganglion 2. Gut 3rgans were snap frozen on dry ice an 4174S/MS 10 B V Ir
,I
-"rrar*n*Mrra~*r I-Dlr~YICC"~II C until used.
Preparation of antigens Guts were suspended in 25 mM Tris buffer containing 132.5 mM NaCI. and 1 mM Na 2 EDTA, pH 7,2, (antigen buffer) and were homogenized in a manual Dowise homogenizer. The homogenate are sonicated using 30-60 second bursts for a total of 1.0 minutes. Sonication wias followed by centrifugation at 600 g for 10 minutes.
Pellets were rehomogenized in an aliquot of supernatant and soni cated as above for a further 5 minutes, The sonicated preparations were pooled and centrifuged at 15,000 g for 20 minutes and the cell pellet was discarded. The supernatant was then subjected to centrifugation at 100,000 g for 1 h. The supernatant thus obtained was retained (soluble protein fraction) and the membrane pellet resuspended by homogenization in antigen buffer. Soluble and membrane fractions were stored at C until used,, All steps described above were carried out in ice baths, Synganglia ere forced through a fine mesh using S a pestle. The cell suspension was collected in antigen S buffer and 'rozen at -20 C until used, UVaccination preparation Solubl.e protein fractions and cell suspensions were emulsified in an equal volume of Freunds incomplete adjuvant. Membrane protein fractions were suspended in antigen buffer containing 1 mg saponin (Quil A) per ml, All vaccine preparations were made up on the day of immunization.
Administration of vaccines Vaccine prep :rations were administered intramuscularly using in 18 g needle as set out in Table 2. Membrane preparations were inoculated in the middle third of the right side of the neck, soluble protein preparations were administered in the middle third of the left neck and cell 4174S/MS 11
-J
suspensions tw*ore inoculaf-ed into the middle Wh~rd of the semimembranosus seritendinous muscles of the left hind leg, Control an-imals were either uninoculated or received adjuvant plus saline. Vaccines were administered on day 0, 11. and '1.2 of the experiment, Blood sampling procedures Animals were bled from the jugular vein at regular intervals; serum was collected by centrifugation and stored at -20 0C Challenge trial The cattle were exposed to tick larvae, (ten days old; 14 4 a M4 20*4 .9' '4 4).
rA 417 4 MS 12 4. 4W~A QI.. 7~ 77 j TABLE 2 Vacc ine program concentrations Time (days) and mode of presentation of -antigen 0 Membrane Soluble 14 Membrane Soluble 42 Membrane Soluble Vaccine group 1. Gut plus synganglia 2. Uninoculated cntro is 3. Adjuvant only controls of animals 350A 500 S00 100 500 50 500 Synganglia were administered as single cell suspensions A Protein conceni.rations are in micrograms 4'*5 a a 4 *t 4 a a a a a 6.
4 0 4 .0 a 449 4 44* 9 604 a 44 £4 0 eta a
I
§1 20,000 per infestation) which wkere placed on the cattle on five occasions at seven-day interuals. All normal and damaged ticks were collected and counted and~ their production of eggs and larvae determined.
RESULTS
Table 3 r at *4* a a a op a.
a 0*I* mao.
0 0 0. 0* S a SaO .5 S a *0 a a a.
0S a t 25 TICK NUMBERS EGG WT.
grams normal damaged total ininoculated controls 17380 1599 18988 2276 ;djuvant controls 17798 987 18785 1787 3ynganglion gut 820 2240 8060 54 Percent protection by vaccine:- Normal Ticks Total Ticks 81% Eggs 97% B) PREPARATION OF AFFINITY COLUMN Sera from the immune cattle were precipitated with S. 50% ammoniuIm sulphate for '1 hours at room temperature.
Follow.ing extensive dialysis against affinity coupling buffer; 0.1 M NatlCO 3 0. 5 M NaCl, P.H. 8.5 1.00 mgs of immunoglol'3ulins (Igs) were coupled to 10 ml of cyanogen bromide activated tepharose 18 gel. Remaining reactive sites were blocked with 0.2 M glycine buffer pH. Follow-ing coupling and washing, gels were packed in 15 ml columrns Normal Igs from control animals, subsequently proven to be highly susceptible to ticks, were also 4.17 4S/MS ji m 2^^ 3 .^l 1 ^*fl 1 ur lcoupled to gel and ciluimns were prepared as previously.
In addition, activated Sepharose 4B gel was blocked by 0.2M glycine buffer, p.H. 8.0, and used to control non-specific absorbtion of proteins to gel, C) CHROMATOGRAPHIC EXTRACTION OF ANTIGENS Large qulantities of eggs (10 gms 100 gmis,) collected over a 7-day laying period from batches of female ticks, were hatched in containers. The 10 day old larvae were frozen for 1 hour, separated from the egg debris, and extracted as described for gut vaccine (see P) Antigens were dialyzed in affinity buffer (PBS p.H.
7,1) and 50 mgm protein was applied t-o the loaded affinity column. Antigen was incubated on the column for 15 minutes, then the column was extensively washed with PBS h-1 p.H. 7.4. at 20 ml/hr until baseline O.D. readings at 280 nm were re-established. Glycine buffer 0.1 M, p.H.
2.8 was applied and fractions were collected until baseline 0,0. readings were again re-established. The column was stored in Tris buffer containing sodium azide and regenerated the folloiwing day using high and low pH buffer cycles.
St Particulate and soluble fractions from larval tick 2 homogenates were both separately chromatographed in this 25 way. The particulate fraction was first treated with Triton X-100 but was not centrifuged. Both soluble and particulate materials were subsequently specifically e l eluted together.
D) VACCINATION OF CATTLE Affinity chromatographed larval antigens were formulated as for gut antigens (see above) and administered to cattle on days 0, 28 and 12 to a total of 500 micrograms of protein per animal.
4174S/MS 15 ii
RESU
Vac c Whol (Sol.
Aff i from (Sol Li-s mne.Group Table 4 Percent Protection (Total, Ticks) (Eggs) e larval homogenate uble plus parLiculate) nity purified fraction whole larval homogenate Uble plus particulate) 16% 65% 84.% *0 0 W ,t EXAMPLE TI Efficacy of Vaccines based on dissected tick organs Method Guts and synganglia are dissected from adult ticks as descr-ibed i.n Example TI Vaccines are prepared and administered to cattle, either gut preparations (soluble and particulate) or synganglion (cell suspension) or both together, as described in Example II and Table Cattle are infested with ticks and immunity assessed as described in Example IT(A).
a 4 r Results Percent Protection against three successive weiekly challenges commenced on day 56 of trial:t Total Ticks Synganglion plut~s guit gut alone 79% 88% 91% 96% tb) Percent Protection againi1-. naturaL Inrestations at approximately 6 months after first vaccination:- Synganglion plus gut Gut. alone 65% (ticks) 4.174S/MS 16 I/ i 4 :i It Thus whilst the protection given by synganglion plus gut is comparable to gut alone at 56 days, the long term protection at 6 months is markedly superior.
These results are shown in more detail in Figure 1.
Figure 1 shows the cumulative drop of ticks from 2 groups of vaccinated cattle compared to the mean cumulat.iue tcks dropped by controls. Group 1 was vaccinated with antigen derived from both synganglion and gut. Group 2 was vaccinated with antigen from gut alone.
The level of immunity (percent protection) was determined by challenging the two groups and the controls with pulse infestations oF 20,000 B microplus larvae; and also by natural infestation in tick-infested pasture.
The results show enhanced long-term protection in Group 1 (synganglion and gut) relative to Group 2 (gut alone) relative both to pulse and natural tick challenges. There is also a degree of natural immunity in controls.
a*
*S
*a* 4174S/MS 17 i r .1 TABLE 5_ Vaccines administered to animals in Example III Antigen Animal Gut membrane Gut supernatant Synganglion.
1 2 3 1 2 3 1 2 3 2 7, 2 8 29, 313 350 100 s0 500 So0 500 31, 32 33, 34, 350 100 50 500 500 500 500 75 50 00 36, 37- 38, 39 (Controls) 0P 4 U S S S 40 S S S 4 5 5 5 55 S S S S S S S 454 S 555 *5 S 05 5 4

Claims (13)

1. An antigenic composition for aiding in the control of ticks which comrnprises antigenic material derived from the synganjlioni of the tick.
2. A composition according to claim 1 wherein the -ynganglion-containing antigenic material is derived from tick larvae.
3. A composition according to claim or 2 which further comprises antigenic material derived from the gut of the tick. 15 4. A composition according to any preceding claim which further comprises antigenic material from tick larvae. the
10. A v anti chrc iner of rai. accc
11. A v tic]
12. A v; whe lar
13. Ap mat G qq ra a.P a a a G a t t a a tat 2 Gt** 'a1 a, a 44 sar a a a.r a aaa. a a a. aatt a itft? An antigenic composition wherein the antigenic material has been purified by affinity chromatography using antibodies bound to a suitable inert support as the means for selective adsorption of specific antigens and wherein the antibodies are raised by immunisation of animals with a composition according to any one of the preceding claims. 6. A composition according to any preceding claim wherein the tick is BooPhilus microplus. 7. A composition according to any preceding claim which further comprises saponin as an adjuvant. 8. A vaccine which comprises antigenic material derived from the synganglion of the tick together with a saponin as a vaccine adjuvant. 9. A vaccine according to claim 8 which further comprises antigenic material derived from the gut of Itt a
14. Ap tic
15. Ap supJ 4174S/tmd 19 4S/ tmd /1: the tick. A vaccine according to claim 8 or 9 wherein the antigenic material has been purified by affinity chromatography using antibodies bound to a suitable inert support as the means for selective adsorption of specific antigens and wherein the antibodic are raised by immunisation of animals with a comp ition according to any one of claims 1 to 4. 11. A vaccine according to claim 8, 9 or 10 wherein the tick is Boophilus microplus. 12. A vaccine according to any one of claims 8 to 11 15 wherein the antigenic material is derived from tick 1* larvae. S. 13. A process for the production of purified antigenic material derived from a tick, which comprises: i. preparation of antibodies bound to a suitable inert support, wherein the antibodies are raised by immunisation of animals with a I composition according to any one of claims 1 to 4; ii. contacting crude tick extract with the supported antibodies; iii. eluting purified antigenic material from the supported antibodies. 14. A process according to claim 13 wherein the crude tick extract is derived from tick larvae. A process according to claim 13 or 14 wherein the supported antibodies used for the purification of 0 1'4S/tmd 20 r i r arastrw f w w i I I antigenic material are derived from blood serum from cattle successfully immunised against ticks. S
16. A process according to claim 13, 14 or 15 wherein the supported antibodies used for the purification of antigenic material are monoclonal antibodies produced from tick antigenic material.
17. A method for the control of tick infestation of a warm blooded animal which comprises immunising the animal with an antigenic composition or a vaccine according to any one of claims 1 to 12.
18. An antigenic composition according to claim 1, 2, 3, or 4 substantially as described with reference to Example I or II.
19. A tick vaccine according to any one of claims 8 to 12 substantially as described in Example I or II. A process for the production of purified antigenic material according to claim 13, 14, 15 or 16 substantially as described in'Example I or II. DATED this 25th day of October 1989 COOPERS ANIMAL HEALTH AUSTRALIA LIMITED By their Patent Attorney GRIFFITH HACK CO. *41* 4 a''r r t d -v^ 174 tnd 21 4f
AU59707/86A 1985-07-03 1985-07-03 Tick vaccine Ceased AU592997B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59707/86A AU592997B2 (en) 1985-07-03 1985-07-03 Tick vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU59707/86A AU592997B2 (en) 1985-07-03 1985-07-03 Tick vaccine
AUPH1310 1985-07-03

Publications (2)

Publication Number Publication Date
AU5970786A AU5970786A (en) 1987-01-08
AU592997B2 true AU592997B2 (en) 1990-02-01

Family

ID=3744955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59707/86A Ceased AU592997B2 (en) 1985-07-03 1985-07-03 Tick vaccine

Country Status (1)

Country Link
AU (1) AU592997B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84574A (en) * 1986-11-27 1994-10-07 Biotech Australia Pty Ltd Antigen from cattle tick, parts, homologues and epitopes thereof having similar immunological activity, process for preparing them, polynucleotide encoding them, vaccines containing them, antibodies derived therefrom and method for protecting animals against tick infestation
CA1339466C (en) * 1986-11-27 1997-09-16 Law Anthony Yorke Johnston Vaccine
US5587311A (en) * 1986-11-27 1996-12-24 Biotechnology Australia Pty. Ltd. DNA encoding a cell membrane glycoprotein of a tick gut

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4593685A (en) * 1984-08-08 1986-02-13 Commonwealth Scientific And Industrial Research Organisation Antigenic extracts derived from boophilus microplus
AU569252B2 (en) * 1982-07-12 1988-01-28 Commonwealth Scientific And Industrial Research Organisation Tick paralysis vaccines and toxins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569252B2 (en) * 1982-07-12 1988-01-28 Commonwealth Scientific And Industrial Research Organisation Tick paralysis vaccines and toxins
AU4593685A (en) * 1984-08-08 1986-02-13 Commonwealth Scientific And Industrial Research Organisation Antigenic extracts derived from boophilus microplus

Also Published As

Publication number Publication date
AU5970786A (en) 1987-01-08

Similar Documents

Publication Publication Date Title
Smith Protection in lambs immunised with Haemonchus contortus gut membrane proteins
DE68928432T2 (en) LEGIONELLOSIS VACCINE AND PRODUCTION METHOD
James et al. The influence of adjuvant on induction of protective immunity by a non-living vaccine against schistosomiasis.
Ramalho‐Pinto et al. Murine Schistosomiasis mansoni: anti‐schistosomula antibodies and the IgG subclasses involved in the complement‐and eosinophilmediated killing of schistosomula in vitro
Launais et al. Hog cholera virus: active immunization of piglets with the Thiverval strain in the presence and absence of colostral passive immunity
JPH0710774A (en) Vaccine for sprepto coccus switzerland infection
US6528058B1 (en) Saponin adjuvant composition
JP2756321B2 (en) Antigen solution containing zinc hydroxide or iron hydroxide as adjuvant
EP0208507B1 (en) Tick vaccine
AU592997B2 (en) Tick vaccine
JP4714167B2 (en) Ericeperross luciopasie antigen and vaccine composition
US5176910A (en) Treponema hyodysenteriae hemolysin and uses therefor
Ekstedt Studies on Immunity to Staphylococcal Infection in Mice: IV. The Role of Specific and Nonspecific Immunity [with Discussion]
Arnesen et al. Immunological responses in Atlantic salmon, Salmo salar L., against purified serine protease and haemolysins from Aeromonas salmonicida
EP0587636B1 (en) Fish vaccine for aeromonas salmonicida infection
Stone et al. Immunization of rabbits to produce high serum titres of neutralizing antibodies and immunity to the paralyzing toxin of Ixodes holocyclus
US4465665A (en) Detoxified E. coli neurotoxin, preparation thereof and immunological preparations containing it
Relyveld et al. Preparation of highly immunogenic protein conjugates by direct coupling to glutaraldehyde-treated cells: Comparison with commonly used preparations
Keppie et al. The immunization of guinea-pigs and mice with a whole-culture extract of a smooth and a rough strain of Brucella abortus
AU746127B2 (en) Saponin adjuvant composition
IE48464B1 (en) A method for the prevention or reduction of fly strike in sheep
DD297560A5 (en) PROTECTIVE VACCINE AGAINST PIG HAEMOPHILOSE
Walker et al. The Immunizing Value of High Egg Passage Flury Rabies Virus and Its Use in Combination with the Virus of Canine Distemper
Ruckli Subkutane Anwendung des Freundschen Adjuvans bei Kaninchen zur Gewinnung von Antikörpern gegen verschiedene Antigene
MXPA00000173A (en) Erysipelothrix rhusiopathiae antigens and vaccine compositions